CRISPR Therapeutics AG — Director's Dealing 2022

Aug 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2022-08-16

Reporting Person: Kulkarni Samarth (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-16	Restricted Stock Units	$	A	25000	Acquired		Common Shares (25000)	Direct
2022-08-16	Performance-based Restricted Stock Units	$	A	150000	Acquired		Common Shares (150000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2: The restricted stock units shall vest in full on August 16, 2025, subject to continued service to the Company or any of its subsidiaries.

F3: Each performance-based restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F4: Represents the maximum number of shares of CRSP Common Shares that may be awarded upon the achievement of performance conditions.

F5: This grant is subject to both time- and performance-based vesting. Performance-based restricted stock units will vest subject to the terms and conditions of the grant agreement evidencing the award and the Company's 2018 Stock Option and Incentive Plan. The performance conditions shall be deemed satisfied subject to achievement of certain share price targets on or before the third anniversary of the date of grant. All of the performance-based restricted stock units that have satisfied the applicable performance-based criteria shall be deemed vested on the third anniversary of the date of grant, subject to continued service to the Company or any of its subsidiaries through such date.